Header

Pediatric Neuroblastoma Clinical Trials

Category:Pediatric
Status:Active

Displaying all 9 trials

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat

This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is be...

Diagnosis: Pediatric Neuroblastoma

Phase: 2

Protocol Number: 14-184

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissue...

Diagnosis: Pediatric Neuroblastoma

Phase: 1

Protocol Number: 15-243

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigat...

Diagnosis: Pediatric Neuroblastoma

Phase: 1

Protocol Number: 14-494

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to child...

Diagnosis: Pediatric Brain Tumor, Pediatric Solid Tumors, Pediatric Sarcoma, Pediatric Neuroblastoma

Phase: 1

Protocol Number: 16-196

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containi...

Diagnosis: Pediatric Neuroblastoma

Phase: 0

Protocol Number: 16-234

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer i...

Diagnosis: Pediatric Neuroblastoma

Phase: N/A

Protocol Number: 00-272

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treat...

Diagnosis: Pediatric Neuroblastoma

Phase:

Protocol Number: 14-449

Neuroblastoma Precision Trial

This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established mu...

Diagnosis: Pediatric Neuroblastoma

Phase:

Protocol Number: 16-624

Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in...

Diagnosis: Pediatric Brain Tumor, Pediatric Neuroblastoma

Phase:

Protocol Number: 17-393

'